MedTrace Logo

Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

NCT05971381 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2025-02-06

No results posted yet for this study

Summary

To evaluate repigmentation and quality of life after treatment of stable vitiligo lesions using the RECELL Device.

Conditions

  • Vitiligo

Interventions

DEVICE

RECELL® Autologous Cell Harvesting Device

The RECELL Device is for use at the patient's point-of-care for the safe and rapid preparation of Spray-On SkinTM Cells from a small sample of a patient's own skin.

Sponsors & Collaborators

  • Avita Medical

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-14
Primary Completion
2024-07-30
Completion
2025-01-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05971381 on ClinicalTrials.gov